Fredun Pharmaceuticals Limited announces Strategic Launch of Hormone Range Products.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fredun Pharmaceuticals has announced the launch of its new 'Hormone Range Products' brand, targeting the longevity, hormone health, recovery science, and human performance therapeutics market. The initial portfolio includes therapies based on testosterone, nandrolone, growth hormone solutions, and hormone optimization therapies. The company describes this as a doctor-led, evidence-backed platform with a digital-first patient engagement model. Fredun reported FY25 revenues of ₹456 Crore with EBITDA of ₹55 Crore and PAT of ₹21 Crore. The company sees this as moving up the value chain into high-growth, precision-driven therapeutic categories.
The launch diversifies Fredun into premium specialty therapeutics with higher margins, positioning the company in the growing preventive healthcare and performance wellness segments. While this is strategically positive for long-term growth, no immediate revenue impact or specific order values have been disclosed for the new product range.